Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean

Effectiveness of Chinese COVID-19 Vaccines in Latin America and the Caribbean

This multi-country study seeks to collect real-world evidence (RWE), from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes, and when administered in different schedules.

This multi-country study seeks to collect RWE, from Latin American and Caribbean countries, on the effectiveness of China-made COVID-19 vaccines in different populations, against different clinical outcomes and when administered in different schedules.

The vaccines of interest are the following:

• 'Sinovac-CoronaVac' (Sinovac Biotech Ltd., Beijing, China),
• 'BIBP COVID-19 Vaccine' ('Covilo'; 'BIBP-CorV') (Sinopharm, Beijing Institute of Biological Products, China),
• 'Convidecia' ('AD5-nCOV') (CanSino Biologics, Tianjin, China).

Inclusion Criteria

Patients need to fulfill all the following criteria to be eligible for the study:

• Being 18 years old or older
• Ever eligible for vaccination2 with any of the Chinese COVID-19 vaccines provided in their country as per national/regional immunization recommendations prior to hospital admission
• ER consultation or hospitalization due to SARI
• Willing and able to provide informed consent (or by a legally accepted representative if the patient is not able to provide a signature by him/herself)

Exclusion Criteria

Patients that fulfill one or more of the following criteria will not be eligible for the study:

• Patients vaccinated against COVID-19 but not with the vaccines of interest
• Patients admitted or hospitalized for other condition than SARI
• Patients to whom it is not possible to perform a diagnostic test (antigen or PCR) for SARS-CoV-2